Prevalence of extended spectrum beta-lactamase producing anaerobic bacteria in chronic periodontitis

Due to the rampant use of antibiotics bacteria are acquiring resistance to penicillin group of drugs, which results in prescription failure in clinical practice. Beta-lactamase producing organisms are not only more virulent they also cause surrounding bacteria to become resistant. Hence, this study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Indian Society of Periodontology 2014-09, Vol.18 (5), p.567-569
Hauptverfasser: Benachinmardi, Kirtilaxmi Kenchappa, Nagmoti, Jyoti, Kothiwale, Shaila, Metgud, Sharada Chidananda
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Due to the rampant use of antibiotics bacteria are acquiring resistance to penicillin group of drugs, which results in prescription failure in clinical practice. Beta-lactamase producing organisms are not only more virulent they also cause surrounding bacteria to become resistant. Hence, this study was undertaken to know the prevalence of extended spectrum beta-lactamase (ESBL) producing anaerobic bacteria in chronic periodontitis. The present study was conducted for a period of 1 year from January to December 2010 at a tertiary care teaching hospital. Clinical samples were collected from the sub gingival pockets from cases of chronic periodontitis and transported to the laboratory in fluid thioglycollate medium. Gram's staining was performed and anaerobic culture put up. All the anaerobic bacteria isolated were tested for beta-lactamase production by Nitrocefin disc method. A total of 60 samples yielded 121 isolates, out of which 26% were ESBL producers. Bacteroides fragilis was the most common organism followed by Fusobacterium species. ESBL producing anaerobic bacteria exits in chronic periodontitis cases and the present study identified 26% of the isolates to be ESBL producers. Antibiotic resistance testing is essential before starting the therapy and in emergency cases drugs should be chosen to cover ESBL producers.
ISSN:0972-124X
0975-1580
DOI:10.4103/0972-124X.142442